A notable advancement in diabetes management is emerging with the approval of tirzepatide at a dosage of 45mg. This new formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://deaconqwvb789547.wikimeglio.com/10569318/groundbreaking_approach_tirzepatide_45mg_for_diabetes_control